0001062993-20-001318.txt : 20200311
0001062993-20-001318.hdr.sgml : 20200311
20200311104217
ACCESSION NUMBER: 0001062993-20-001318
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20200311
DATE AS OF CHANGE: 20200311
EFFECTIVENESS DATE: 20200311
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tassili Life Science Corp.
CENTRAL INDEX KEY: 0001806185
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-362494
FILM NUMBER: 20704278
BUSINESS ADDRESS:
STREET 1: 366 BAY STREET, SUITE 200
CITY: TORONTO
STATE: A6
ZIP: M5H 4B2
BUSINESS PHONE: 416-270-9566
MAIL ADDRESS:
STREET 1: 366 BAY STREET, SUITE 200
CITY: TORONTO
STATE: A6
ZIP: M5H 4B2
D
1
primary_doc.xml
X0708
D
LIVE
0001806185
Tassili Life Science Corp.
366 BAY STREET, SUITE 200
TORONTO
A6
ONTARIO, CANADA
M5H 4B2
416-270-9566
ONTARIO, CANADA
None
None
Corporation
true
2018
Jonathan
Held
366 Bay Street
Suite 200
Toronto
A6
ONTARIO, CANADA
M5H 4B2
Executive Officer
Director
Jonathan
Gilbert
366 Bay Street
Suite 200
Toronto
A6
ONTARIO, CANADA
M5H 4B2
Executive Officer
Director
George
Scorsis
366 Bay Street
Suite 200
Toronto
A6
ONTARIO, CANADA
M5H 4B2
Director
Maghsoud
Dariani
366 Bay Street
Suite 200
Toronto
A6
ONTARIO, CANADA
M5H 4B2
Executive Officer
Other
Decline to Disclose
- 06b
false
2020-02-21
false
true
true
true
true
true
Convertible Debentures bearing interest of 8% per annum, convertible into units or common shares of the Company subject to certain terms and conditions in connection with a Go Public Transaction.
true
Convertible Debentures bearing interest of 8% per annum, convertible into units or common shares of the Company subject to certain terms and conditions in connection with a Go Public Transaction.
0
300211
300211
0
Convertible Debentures bearing interest of 8% per annum, convertible into units or common shares of the Company subject to certain terms and conditions inconnection with a Go Public Transaction.
false
10
0
0
0
false
Tassili Life Science Corp.
/s/ Jonathan Held
Jonathan Held
Chief Financial Officer
2020-03-11